DelveInsight’s “Ascites Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Ascites, historical and forecasted epidemiology as well as the Ascites market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Ascites market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Ascites Market Forecast
Some of the key facts of the Ascites Market Report:
-
The Ascites market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
-
In November 2024, Pharmanovia, an international pharmaceutical company specializing in commercializing innovative therapies and enhancing the lifecycle of established medicines, announced the expansion of its oncology portfolio through a new licensing agreement for catumaxomab, aimed at treating malignant ascites.
-
In 2023, the US ascites market size attributed to cirrhosis was valued at over USD 800 million, with projections indicating growth throughout the forecast period (2024–2034).
-
In 2023, the market size for diuretics used in the treatment of ascites caused by cirrhosis in the US was estimated to be approximately USD 140 million.
-
In 2023, the US had the highest number of ascites cases caused by cirrhosis among the 7MM, exceeding 152,000 cases. This figure is expected to rise throughout the forecast period (2024-2034).
-
In 2023, breast cancer contributed the highest number of ascites cases caused by malignancies in the US, with approximately 13,000 cases, followed by colorectal cancer.
-
In the US, severity-specific cases of Grade II and III ascites totaled approximately 125,000 in 2023.
-
Key Ascites Companies: PharmaIN, AstraZeneca plc, Pfizer Inc., Novartis AG, Baxter International Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, Merit Medical Systems Inc., Neovii Pharmaceuticals AG, GI Supply, BioVie, Ocelot Bio, Movetis, Sanofi, Otsuka Beijing Research Institute, Grifols Therapeutics LLC, Norgine, and others
-
Key Ascites Therapies: PHIN-214, BIV201 (Terlipressin), OCE-205, catumaxomab, M0002, satavaptan (SR121463B), Tolvaptan, Albumin, Rifaximin, and others
-
The Ascites market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Ascites pipeline products will significantly revolutionize the Ascites market dynamics.
Ascites Overview
A surplus of intraperitoneal fluid is referred to as ascites (hydroperitoneum is a rare synonym). Ascites is a disorder where fluid builds up in the abdominal cavities. Ascites may be painful in extreme cases.
Get a Free sample for the Ascites Market Report
https://www.delveinsight.com/sample-request/ascites-market
Ascites Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Ascites Epidemiology Segmentation:
The Ascites market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
-
Total Prevalence of Ascites
-
Prevalent Cases of Ascites by severity
-
Gender-specific Prevalence of Ascites
-
Diagnosed Cases of Episodic and Chronic Ascites
Download the report to understand which factors are driving Ascites epidemiology trends @ Ascites Epidemiology Forecast
Ascites Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ascites market or expected to get launched during the study period. The analysis covers Ascites market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Ascites Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Ascites Therapies and Key Companies
-
PHIN-214: PharmaIN
-
BIV201 (Terlipressin): BioVie
-
OCE-205: Ocelot Bio
Discover more about therapies set to grab major Ascites market share @ Ascites Treatment Market
Ascites Market Strengths
-
The rise in the patient population of underlying conditions of ascites such as liver cirrhosis, alcoholism, kidney or heart failure, malignancy, etc. might contribute to an increase in the patient population of ascites
Ascites Market Opportunities
-
Limited approved, and emerging therapies in the pipeline offer a great opportunity for the investment and development of novel therapies
Scope of the Ascites Market Report
-
Study Period: 2020–2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Ascites Companies: PharmaIN, AstraZeneca plc, Pfizer Inc., Novartis AG, Baxter International Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, Merit Medical Systems Inc., Neovii Pharmaceuticals AG, GI Supply, BioVie, Ocelot Bio, Movetis, Sanofi, Otsuka Beijing Research Institute, Grifols Therapeutics LLC, Norgine, and others
-
Key Ascites Therapies: PHIN-214, BIV201 (Terlipressin), OCE-205, catumaxomab, M0002, satavaptan (SR121463B), Tolvaptan, Albumin, Rifaximin, and others
-
Ascites Therapeutic Assessment: Ascites current marketed and Ascites emerging therapies
-
Ascites Market Dynamics: Ascites market drivers and Ascites market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Ascites Unmet Needs, KOL’s views, Analyst’s views, Ascites Market Access and Reimbursement
To know more about Ascites companies working in the treatment market, visit @ Ascites Clinical Trials and Therapeutic Assessment
Table of Contents
1. Ascites Market Report Introduction
2. Executive Summary for Ascites
3. SWOT analysis of Ascites
4. Ascites Patient Share (%) Overview at a Glance
5. Ascites Market Overview at a Glance
6. Ascites Disease Background and Overview
7. Ascites Epidemiology and Patient Population
8. Country-Specific Patient Population of Ascites
9. Ascites Current Treatment and Medical Practices
10. Ascites Unmet Needs
11. Ascites Emerging Therapies
12. Ascites Market Outlook
13. Country-Wise Ascites Market Analysis (2020–2034)
14. Ascites Market Access and Reimbursement of Therapies
15. Ascites Market Drivers
16. Ascites Market Barriers
17. Ascites Appendix
18. Ascites Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
